Navigation Links
Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Date:11/2/2010

and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences include, among others, risks relating to: the successful preclinical development of our product candidates; the completion of our clinical trials; the review process of the FDA, the EMEA, other foreign regulatory bodies and other governmental regulatory bodies, including the FDA's and the EMEA's review of any filings we make in connection with the treatment protocol for taliglucerase alfa and including the risk that regulatory authorities may find that the data from our clinical trials and other studies is insufficient for regulatory approval; delays in the FDA's, the EMEA's or other health regulatory authorities' approval of any applications we file or refusals to approve such filings, including the NDA we filed with the FDA for taliglucerase alfa for the treatment of Gaucher disease; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application we file for any such drug product; and other factors described in our filings with the Securities and Exchange Commission. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings for such clinical trials. Further, even if favorable testing data is generated by clinical trials of drug products, the FDA, EMEA or any other foreign regulatory authority may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug product. Failure to obtain approval from the FDA, EMEA or any other foreign regulatory authority of any of our drug candidates in a timely
'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
2. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
3. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
4. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
5. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... March 25, 2011 Soles4Souls, the international shoe charity ... their proceeds from orders to Soles4Souls, to help provide ... 9.0 magnitude earthquake that rocked Japan on March 9, ... Pharmacy; call 877-323-9803 for your prescriptions, medical supplies, and ...
... AssureRx Health, Inc. today announced the closing ... medicine company, which provides clinically-relevant information to help physicians ... individual neuropsychiatric patients, will use the funds to expand ... GeneSightRx®, and for second generation product development activities. ...
Cached Medicine Technology:PromiseCare Pharmacy Donates to Soles4Souls® Japanese Relief Efforts 2AssureRx Health Raises $11 Million Series B Financing 2AssureRx Health Raises $11 Million Series B Financing 3AssureRx Health Raises $11 Million Series B Financing 4
(Date:4/23/2014)... known as Ritalin, may prevent the depletion of self-control, ... a journal of the Association for Psychological Science. , ... or trying to focus attention on a boring textbook ... potential explanation for this difficulty: Exerting self-control for a ... self-control effectively on subsequent tasks. , "It is as ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... last few decades researchers have characterized a set of ... behavior in all types of species, from flies to ... but researchers surmise there are more. A team from ... Pennsylvania wondered if big-data approaches could find them. ... John Hogenesch, PhD, professor of Pharmacology and first author ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
Breaking Medicine News(10 mins):Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... Health Services, Inc. (NYSE: UHS ) announced ... a cash dividend of $0.08 per share on June ... 1, 2009.Universal Health Services, Inc. is one of the ... care and behavioral health hospitals, and ambulatory centers nationwide ...
... Examined For Skin CancerYONKERS, N.Y., May 20 Thirty-one percent of ... National Research Center said they never wear sunscreen. ... of those polled said they,d been examined by a doctor for ... of Consumer Reports rates ten top selling sunscreens to ...
... the strain is related to flu variant that circulated before ... people may have partial immunity to the new H1N1 swine ... strain circulating prior to 1957, a U.S. infectious-disease expert said ... more likely you are to have been exposed to H1N1 ...
... when even teens who have never tried a drop of alcohol ... big events and there will be multiple parties to attend and ... , Assume that your child will be tempted to drink alcohol ... Inside Alcohol Project of the American Association for the Advancement of ...
... Small Business Membership process, which eliminates more than a dozen formal ... qualify with a business card or letterhead. , ... ... series of pro-small business initiatives aimed to help small business owners ...
... Orasi Medical, Inc. announced today that it has completed ... use this capital to expand the development and use ... markets. Pharmaceutical companies will use this test to determine ... diseases. Orasi is currently in discussions with several pharmaceutical ...
Cached Medicine News:Health News:Consumer Reports Poll: Thirty-One Percent of Americans Never Use Sunscreen 2Health News:Consumer Reports Poll: Thirty-One Percent of Americans Never Use Sunscreen 3Health News:Consumer Reports Poll: Thirty-One Percent of Americans Never Use Sunscreen 4Health News:Older Adults May Have Some Immunity to Swine Flu 2Health News:Older Adults May Have Some Immunity to Swine Flu 3Health News:Older Adults May Have Some Immunity to Swine Flu 4Health News:Older Adults May Have Some Immunity to Swine Flu 5Health News:Older Adults May Have Some Immunity to Swine Flu 6Health News:Older Adults May Have Some Immunity to Swine Flu 7Health News:Older Adults May Have Some Immunity to Swine Flu 8Health News:Older Adults May Have Some Immunity to Swine Flu 9Health News:Older Adults May Have Some Immunity to Swine Flu 10Health News:Older Adults May Have Some Immunity to Swine Flu 11Health News:Older Adults May Have Some Immunity to Swine Flu 12Health News:Older Adults May Have Some Immunity to Swine Flu 13Health News:Use science to convince teens a sober prom is better, AAAS says 2Health News:National Small Business Week Update: Sam's Club Announces Simplified Small Business Membership; Partnership With U.S. Chamber of Commerce, Plus Free One-Day Pass 2Health News:National Small Business Week Update: Sam's Club Announces Simplified Small Business Membership; Partnership With U.S. Chamber of Commerce, Plus Free One-Day Pass 3
First to USA-market, this revolutionary technology combines CBC and CRP analysis for stat results of 17 parameters within 4.5 minutes!...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
... 5.5x magnification., ,Higher magnification for advanced ... true image. Edge to edge clarity ... for intricate surgical applications. The XL's ... anti-reflective coating to produce a superior ...
... and 3.0x magnification. The true benefit of ... while maintaining focal clarity is made possible ... The lightweight aluminum bar and individual pupillary ... and optimal focal alignment, eliminating headache and ...
Medicine Products: